vs

Side-by-side financial comparison of NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $23.6M, roughly 1.9× NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP). PACIFIC BIOSCIENCES OF CALIFORNIA, INC. runs the higher net margin — -90.4% vs -677.3%, a 586.9% gap on every dollar of revenue. On growth, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP posted the faster year-over-year revenue change (15.7% vs 13.8%). Over the past eight quarters, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP's revenue compounded faster (8.9% CAGR vs 7.3%).

New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

NEN vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.9× larger
PACB
$44.6M
$23.6M
NEN
Growing faster (revenue YoY)
NEN
NEN
+1.9% gap
NEN
15.7%
13.8%
PACB
Higher net margin
PACB
PACB
586.9% more per $
PACB
-90.4%
-677.3%
NEN
Faster 2-yr revenue CAGR
NEN
NEN
Annualised
NEN
8.9%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NEN
NEN
PACB
PACB
Revenue
$23.6M
$44.6M
Net Profit
$-1.4M
$-40.4M
Gross Margin
37.1%
Operating Margin
14.0%
-92.3%
Net Margin
-677.3%
-90.4%
Revenue YoY
15.7%
13.8%
Net Profit YoY
-133.0%
-1802.7%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEN
NEN
PACB
PACB
Q4 25
$23.6M
$44.6M
Q3 25
$23.7M
$38.4M
Q2 25
$21.2M
$39.8M
Q1 25
$20.7M
$37.2M
Q4 24
$20.4M
$39.2M
Q3 24
$20.2M
$40.0M
Q2 24
$20.1M
$36.0M
Q1 24
$19.9M
$38.8M
Net Profit
NEN
NEN
PACB
PACB
Q4 25
$-1.4M
$-40.4M
Q3 25
$-521.8K
$-38.0M
Q2 25
$4.1M
$-41.9M
Q1 25
$3.8M
$-426.1M
Q4 24
$4.2M
$2.4M
Q3 24
$3.9M
$-60.7M
Q2 24
$4.1M
$-173.3M
Q1 24
$3.5M
$-78.2M
Gross Margin
NEN
NEN
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
NEN
NEN
PACB
PACB
Q4 25
14.0%
-92.3%
Q3 25
20.0%
-101.1%
Q2 25
33.3%
-112.8%
Q1 25
30.1%
-1154.5%
Q4 24
32.4%
-390.1%
Q3 24
32.0%
-160.3%
Q2 24
32.6%
-488.3%
Q1 24
28.9%
-209.6%
Net Margin
NEN
NEN
PACB
PACB
Q4 25
-677.3%
-90.4%
Q3 25
-2.2%
-98.9%
Q2 25
19.5%
-105.4%
Q1 25
18.3%
-1146.8%
Q4 24
20.7%
6.0%
Q3 24
19.3%
-151.9%
Q2 24
20.3%
-481.3%
Q1 24
17.4%
-201.4%
EPS (diluted)
NEN
NEN
PACB
PACB
Q4 25
$-0.11
Q3 25
$-0.13
Q2 25
$-0.14
Q1 25
$-1.44
Q4 24
$-0.44
Q3 24
$-0.22
Q2 24
$-0.64
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEN
NEN
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$26.7M
$279.5M
Total DebtLower is stronger
$531.0M
Stockholders' EquityBook value
$5.3M
Total Assets
$505.3M
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEN
NEN
PACB
PACB
Q4 25
$26.7M
$279.5M
Q3 25
$13.4M
$298.7M
Q2 25
$16.7M
$314.7M
Q1 25
$30.9M
$343.1M
Q4 24
$17.6M
$389.9M
Q3 24
$15.1M
$471.1M
Q2 24
$13.5M
$509.8M
Q1 24
$28.8M
$561.9M
Total Debt
NEN
NEN
PACB
PACB
Q4 25
$531.0M
Q3 25
$514.2M
Q2 25
$514.3M
Q1 25
$407.8M
Q4 24
$408.6M
Q3 24
$409.3M
Q2 24
$410.0M
Q1 24
$410.7M
Stockholders' Equity
NEN
NEN
PACB
PACB
Q4 25
$5.3M
Q3 25
$36.1M
Q2 25
$61.5M
Q1 25
$91.6M
Q4 24
$506.6M
Q3 24
$453.1M
Q2 24
$492.7M
Q1 24
$649.0M
Total Assets
NEN
NEN
PACB
PACB
Q4 25
$505.3M
$784.1M
Q3 25
$492.9M
$803.2M
Q2 25
$494.8M
$825.5M
Q1 25
$385.2M
$860.8M
Q4 24
$393.5M
$1.3B
Q3 24
$387.4M
$1.5B
Q2 24
$383.7M
$1.5B
Q1 24
$381.2M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEN
NEN
PACB
PACB
Operating Cash FlowLast quarter
$27.7M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEN
NEN
PACB
PACB
Q4 25
$27.7M
$-19.1M
Q3 25
$2.3M
$-18.7M
Q2 25
$12.5M
$-29.4M
Q1 25
$5.5M
$-44.1M
Q4 24
$31.9M
$-30.6M
Q3 24
$8.5M
$-45.5M
Q2 24
$5.4M
$-54.3M
Q1 24
$6.1M
$-75.7M
Free Cash Flow
NEN
NEN
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
NEN
NEN
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
NEN
NEN
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
NEN
NEN
PACB
PACB
Q4 25
Q3 25
Q2 25
3.02×
Q1 25
1.44×
Q4 24
7.57×
-12.93×
Q3 24
2.17×
Q2 24
1.32×
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEN
NEN

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons